Drug Approval | April 15, 2023
NS Pharma announces FDA clearance to initiate phase II study for an Exon 44 skipping candidate
Study efficacy measures will include the expression of dystrophin protein and motor function.
Study efficacy measures will include the expression of dystrophin protein and motor function.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
The new team members, Solenn Percelay and Noémie Spinelli, will support the organization’s commitment to excellence in humanized mouse model care and use
Clinical Decision Support Systems' huge potential to help ensure that each patient can receive high-quality care; study shows a reduction in diagnostic errors from 24% to 2%
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
NGS enables researchers to quickly sequence entire genomes and transcriptomes of organisms.
The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova
Enabling wireless monitoring In ambulances and homes
Science communication brings behavioural changes
India's strategy against Covid was more effective than any other countries in the world
Subscribe To Our Newsletter & Stay Updated
